OTC:CC - Ocumetics Announces Appointment of President and CEO
(TheNewswire)
Dean Burns, a 27-year Alcon Vision veteran, will leadOcumetics through the clinical trial and commercializationprocess
Calgary, Alberta – TheNewswire - June 12 , 2023 -Ocumetics Technology Corp. (TSXV:OTC)(OTC:OTCFF) (FRA:2QBO) (“ Ocumetics ” or the “ Corporation ”) is pleased to announce that it hasappointed Mr. Dean Burns as Ocumetics’ President and CEO. Mr.Burns will also join the Ocumetics board of directors. Mr. Burns waspreviously a consultant of the Corporation, assisting with theCorporation’s regulatory and marketing endeavours. Further to the announcement of Dr. Mark Lee’s resignationeffective June 30, 2023, Dr. Lee stepped down as President and CEO onJune 12, 2023.
“We are pleased to have Dean move from a consultingcapacity to join our team on a full-time basis in a leadershiprole,” said Dr. Garth Webb, Chairman of the Board of Ocumetics. “Dean will draw on his 27 years of experience navigating theregulatory process and product commercialization with Alcon Vision tolead Ocumetics as we commence clinical trials,” added Dr.Webb.
Mr. Burns is recently retired from Alcon Vision, wherehe was a Senior Director of Cataract Instrumentation and AdvancedConsumable Technology, a US$750 million business of Alcon. At Alcon,Mr. Burns managed technologies in four therapeutic categories:Cataract, Refractive, Retinal and Pharmaceutical. Mr. Burns’ 27-year career with Alcon brings a diversehealthcare experience to Ocumetics. His experience includeddeveloping plans to commercialize acquired technologies and lineextension of existing products. He also has skills and experience inmarketing and sales management, manufacturing, comprehensiveunderstanding of the regulatory process for devices, Key OpinionLeader management, and surgeon clinical training. Mr. Burns’accomplishments include over 15 FDA product approvals and fivebusiness development and licensing acquisition projects totalingUS$2.3 billion.
“I am thrilled to join Ocumetics on a full-timebasis,” said Dean Burns. “Over the past year, in my consultingcapacity, I have seen first-hand the market potential of the Ocumeticslens technology. The potential for this technology is incredible andI look forward to leading the process to bring it to market. My90-day priorities include meeting with shareholders, engaging newinvestors and raising capital to fund our Phase 1 clinical trials.”
In conjunction with his appointment, Ocumetics hasissued 1,600,000 incentive stock options to Mr. Burns. Each optionentitles the holder to purchase one common share of Ocumetics at anexercise price per common share of $0.32 for a period of five years. The options will vest over three years, with 15% of the optionsvesting six months after the date of issuance, another 15% vestingafter 12 months, another 15% after 18 months, another 15% after 24months, another 20% after 30 months and the remaining 20% after 36months.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO) is a Canadian research and development company thatspecializes in adaptive intraocular lens designs. Ocumetics is in thepreclinical study stage of a game-changing technology for theophthalmic industry. Ocumetics has developed an expandableintraocular lens that fits within the capsular bag followingextracapsular cataract extraction. It is designed to allow the eyesnatural muscle activity to shift focus from distance to near,potentially to eliminate the need for corrective lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns, President and CEO
(817) 874-7564
Dayton Marks, Director
(778) 347-2500
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release
Copyright (c) 2023 TheNewswire - All rights reserved.